Apriso Related Published Studies
Well-designed clinical trials related to Apriso (Mesalamine)
Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine)
suppositories in patients with ulcerative colitis and active rectal inflammation
-- a placebo-controlled study. [2013]
Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. [2011.02]
A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis. [2011.02]
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. [2010.11]
Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial. [2010.10]
Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. [2010.04]
Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers. [2010.02]
Direct comparison of two different mesalamine formulations for the induction of
remission in patients with ulcerative colitis: a double-blind, randomized study. [2010]
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. [2009.12]
Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. [2009.07]
Comparison of the analgesic effect of ibuprofen with mesalamine after discectomy surgery in patients with lumbar disc herniation: a double-blind randomized controlled trial. [2009.05]
Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis. [2008.12]
Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. [2008.10]
N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: Randomized, placebo-controlled pilot study. [2008.05.14]
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. [2007.12]
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. [2007.01]
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. [2007.01]
Well-designed clinical trials possibly related to Apriso (Mesalamine)
Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative
colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. [2015]
Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative
colitis - a randomized, placebo-controlled, pilot study. [2014]
Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee
charcoal compared with mesalazine in maintaining remission in ulcerative
colitis--a double-blind, double-dummy study. [2013]
Efficacy and mode of action of mesalazine in the treatment of
diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a
randomised controlled trial. [2013]
Abatacept for Crohn's disease and ulcerative colitis. [2012]
Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of
ulcerative colitis compared with mesalazine: a double-blinded and randomized
study. [2012]
Drug development in inflammatory bowel disease: The role of the FDA. [2011.12]
Individually tailored treatment of medication nonadherence. [2011.10]
Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: A double-blinded and randomized study. [2011.09.06]
The efficacy of the combination therapy with oral and topical mesalazine for patients with the first episode of radiation proctitis. [2011.09]
Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question. [2011.05]
3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. [2011.04]
Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. [2011.04]
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. [2011.03]
Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. [2011.02]
Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. [2011.01]
Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. [2011.01]
Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative
colitis. [2011]
Curcumin for inflammatory bowel disease: a review of human studies. [2011]
Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine
for moderately active ulcerative colitis - new light on a familiar question. [2011]
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4
g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. [2011]
Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on
moderately active ulcerative colitis. A phase III parallel-dosing study. [2011]
Aminosalicylates for induction of remission or response in Crohn's disease. [2010.12.08]
E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. [2010.12]
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. [2010.10]
Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. [2010.08]
Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. [2010.08]
Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide. [2010.08]
Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity. [2010.07]
Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. [2010.06]
Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. [2010.06]
Oral beclomethasone dipropionate in pediatric active ulcerative colitis: a comparison trial with mesalazine. [2010.04]
Efficacy of 5-ASA in the treatment of colonic diverticular disease. [2010.02]
Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. [2009.11.01]
Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study. [2009.11]
Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study. [2009.11]
In vivo effects of mesalazine or E. coli Nissle 1917 on microsatellite instability in ulcerative colitis. [2009.09.15]
[Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease] [2009.09]
Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. [2009.08]
Pharmacokinetics and safety of single and multiple doses of Asacol tablets in Japanese healthy volunteers. [2009.08]
The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: a pilot study. [2009.07]
Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. [2009.06]
Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. [2009.05]
Voting With their Feet (VWF) endpoint: a meta-analysis of an alternative endpoint in clinical trials, using 5-ASA induction studies in ulcerative colitis. [2009.03]
Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. [2009.02]
Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. [2009.02]
Budesonide for maintenance of remission in Crohn's disease. [2009.01.21]
Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial. [2009.01]
Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis. [2009]
The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis. [2008.12.01]
Granulocytapheresis versus methylprednisolone in patients with acute ulcerative colitis: 12-month follow up. [2008.11]
Budesonide for induction of remission in Crohn's disease. [2008.07.16]
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. [2008.07]
Can 5-aminosalicylic acid suppository decrease the pain after rectal band ligation? [2008.06.14]
MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. [2008.06.01]
Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. [2008.05]
Interventions for treating lymphocytic colitis. [2008.04.16]
A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. [2008.01.07]
Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. [2008]
Successful Treatment of Steroid Refractory Active Ulcerative Colitis with Natural Interferon-beta - an Open Long-Term Trial. [2007.12]
Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. [2007.11.01]
Prevention of Complications and Symptomatic Recurrences in Diverticular Disease with Mesalazine: A 12-Month Follow-up. [2007.11]
Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin. [2007.10]
Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. [2007.09]
Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. [2007.09]
Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. [2007.07.01]
A clinical trial on absorption and N-acetylation of oral and rectal mesalazine. [2007.07]
Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease. [2007.06.15]
Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. [2007.06]
Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: A multicenter, randomized, double-blind study. [2007.04]
Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers. [2007.03]
Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. [2007.03]
Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. [2007.02]
Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment? [2007]
Spotlight on VSL#3 Probiotic Mixture in Chronic Inflammatory Bowel Diseases. [2007]
Other research related to Apriso (Mesalamine)
Effect of MMX® mesalamine coadministration on the pharmacokinetics of
amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from
four randomized clinical trials. [2014]
Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of
ulcerative colitis. [2012]
Mesalamine in the treatment and maintenance of remission of ulcerative colitis. [2012]
Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-Analysis. [2011.12]
Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine. [2011.02.27]
Small intestinal release mesalamine for the treatment of refractory celiac disease type I. [2011.01]
Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. [2010.11]
Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. [2010.09]
Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine. [2010.09]
|